Cancer Res Treat.  2012 Jun;44(2):85-96.

Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea

• Kang YK
• Kang HJ
• Kim KM
• Sohn T
• Choi D
• Ryu MH
• Kim WH
• Yang HK
• Korean GIST Study Group (KGSG)

Abstract

Despite their rarity in incidence and prevalence, gastrointestinal stromal tumors (GISTs) have emerged as a distinct and noteworthy pathogenetic entity. The clinical management of GISTs has rapidly evolved due to the recent elucidation of their oncogenic signal transduction pathway and the introduction of molecular-targeted therapies. Successful management of GISTs requires a multidisciplinary approach firmly based on an accurate histopathologic diagnosis. In 2007, the Korean GIST study group published the first guideline for optimal diagnosis and treatment of GISTs in Korea. The second version of the guideline was published in 2010. Herein, we provide the results of relevant clinical studies for the purpose of further revision to the guideline. We expect this new guideline will enhance the accuracy of diagnosis, as performed by members of the Korean associate of physicians involved in GIST patient care, thus improving the efficacy of treatment.

Keyword

Guideline; Gastrointestinal stromal tumors; Diagnosis; Surgery; Drug therapy; Molecular targeted therapy; Imatinib; Sunitinib

MeSH Terms

Benzamides
Gastrointestinal Stromal Tumors
Incidence
Indoles
Korea
Molecular Targeted Therapy
Patient Care
Piperazines
Prevalence
Pyrimidines
Pyrroles
Signal Transduction
Imatinib Mesylate
Benzamides
Indoles
Piperazines
Pyrimidines
Pyrroles

Figure

• 

  Fig. 1 Photomicrograph of a typical spindle cell type gastrointestinal stromal tumor (A, H&E staining, ×200). In the stomach, spindle cells frequently contain many vacuoles (arrows) (B, H&E staining, ×400).

• 

  Fig. 2 In a gastrointestinal stromal tumor (GIST) of the small intestine (A, H&E staining, ×200) the malignant tumor shows typical GIST dedifferentiated histology (B, H&E staining, ×400) and a poorly differentiated sarcoma area (C, H&E staining, ×400).

• 

  Fig. 3 Gastrointestinal stromal tumors which are positive for KIT protein (A, immunohistochemical staining, ×200) and DOG-1 (B, immunohistochemical staining, ×200). Smooth muscle bundles and blood vessels serve as internal negative controls.

Reference

1. NCCN clinical practice guidelines in oncology: soft tissue sarcoma. Version 2.2011 [Internet]. National Comprehensive Cancer Network. 2011. cited 2012 Mar 2. Fort Washington, PA: National Comprehensive Cancer Network;Available from: http://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf .

2. Casali PG, Blay JY. ESMO/CONTICANET/EUROBONET Consensus Panel of Experts. Gastrointestinal stromal tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21(Suppl 5):v98–v102. PMID: 20555113.

3. Nishida T, Hirota S, Yanagisawa A, Sugino Y, Minami M, Yamamura Y, et al. Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version. Int J Clin Oncol. 2008; 13:416–430. PMID: 18946752.

4. Demetri GD, Antonia S, Benjamin RS, Bui MM, Casper ES, Conrad EU III, et al. National Comprehensive Cancer Network Practice Guidelines in Oncology Soft Tissue Sarcoma. J Natl Compr Canc Netw internet. 2011. cited 2012 Mar 2. Fort Washington, PA: National Comprehensive Cancer Network;Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp .

5. Korean Gastrointestinal Stromal Tumor Study Group. Kang YK. Clinical practice guideline for adequate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea. J Korean Med Assoc. 2007; 50:830–841.

6. Kang YK, Kim KM, Sohn T, Choi D, Kang HJ, Ryu MH, et al. Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea. J Korean Med Sci. 2010; 25:1543–1552. PMID: 21060741.

7. Nelson H, Petrelli N, Carlin A, Couture J, Fleshman J, Guillem J, et al. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst. 2001; 93:583–596. PMID: 11309435.

8. Kang DY, Park CK, Choi JS, Jin SY, Kim HJ, Joo M, et al. Multiple gastrointestinal stromal tumors: clinicopathologic and genetic analysis of 12 patients. Am J Surg Pathol. 2007; 31:224–232. PMID: 17255767.

9. Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet. 2007; 369:1731–1741. PMID: 17512858.

10. Kim KM, Kang DW, Moon WS, Park JB, Park CK, Sohn JH, et al. Gastrointestinal stromal tumors in Koreans: its incidence and the clinical, pathologic and immunohistochemical findings. J Korean Med Sci. 2005; 20:977–984. PMID: 16361808.

11. Cho MY, Sohn JH, Kim JM, Kim KM, Park YS, Kim WH, et al. Current trends in the epidemiological and pathological characteristics of gastrointestinal stromal tumors in Korea, 2003-2004. J Korean Med Sci. 2010; 25:853–862. PMID: 20514305.

12. Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)-update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw. 2007; 5(Suppl 2):S1–S29. PMID: 17624289.

13. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003; 21:4342–4349. PMID: 14645423.

14. Miettinen M, Wang ZF, Sarlomo-Rikala M, Osuch C, Rutkowski P, Lasota J. Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am J Surg Pathol. 2011; 35:1712–1721. PMID: 21997692.

15. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006; 130:1466–1478. PMID: 17090188.

16. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002; 33:459–465. PMID: 12094370.

17. Liegl B, Hornick JL, Lazar AJ. Contemporary pathology of gastrointestinal stromal tumors. Hematol Oncol Clin North Am. 2009; 23:49–68. PMID: 19248970.

18. Kang GH, Srivastava A, Kim YE, Park HJ, Park CK, Sohn TS, et al. DOG-1 and PKC-θ are useful in the diagnosis of KIT-negative gastrointestinal stromal tumors. Mod Pathol. 2011; 24:866–875. PMID: 21358619.

19. Kim KM, Kang DW, Moon WS, Park JB, Park CK, Sohn JH, et al. PKCtheta expression in gastrointestinal stromal tumor. Mod Pathol. 2006; 19:1480–1486. PMID: 16892012.

20. Lee HE, Kim MA, Lee HS, Lee BL, Kim WH. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining. J Clin Pathol. 2008; 61:722–729. PMID: 18381383.

21. Orosz Z, Tornóczky T, Sápi Z. Gastrointestinal stromal tumors: a clinicopathologic and immunohistochemical study of 136 cases. Pathol Oncol Res. 2005; 11:11–21. PMID: 15800677.

22. Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira AM, Heinrich MC, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol. 2004; 28:889–894. PMID: 15223958.

23. Miettinen M, Wang ZF, Lasota J. DOG-1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol. 2009; 33:1401–1408. PMID: 19606013.

24. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006; 23:70–83. PMID: 17193820.

25. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol. 1999; 30:1213–1220. PMID: 10534170.

26. Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol. 2005; 16:566–578. PMID: 15781488.

27. Brunicardi FC, Andersen DK, Billiar TR, Dunn DL, Hunter JG, Pollock RE. Schwartz's principles of surgery. 2005. 8th ed. New York: McGraw-Hill.

28. Townsend CM Jr, Sabiston DC. Sabiston textbook of surgery: the biological basis of modern surgical practice. 2004. 17th ed. Philadelphia: W.B. Saunders Co..

29. Trent JC, Benjamin RS. New developments in gastrointestinal stromal tumor. Curr Opin Oncol. 2006; 18:386–395. PMID: 16721136.

30. Ryu MH, Lee JL, Chang HM, Kim TW, Kang HJ, Sohn HJ, et al. Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate. Jpn J Clin Oncol. 2006; 36:17–24. PMID: 16418188.

31. Gold JS, Dematteo RP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg. 2006; 244:176–184. PMID: 16858179.

32. Iwahashi M, Takifuji K, Ojima T, Nakamura M, Nakamori M, Nakatani Y, et al. Surgical management of small gastrointestinal stromal tumors of the stomach. World J Surg. 2006; 30:28–35. PMID: 16369707.

33. Choi SM, Kim MC, Jung GJ, Kim HH, Kwon HC, Choi SR, et al. Laparoscopic wedge resection for gastric GIST: long-term follow-up results. Eur J Surg Oncol. 2007; 33:444–447. PMID: 17174060.

34. Novitsky YW, Kercher KW, Sing RF, Heniford BT. Long-term outcomes of laparoscopic resection of gastric gastrointestinal stromal tumors. Ann Surg. 2006; 243:738–745. PMID: 16772777.

35. Otani Y, Furukawa T, Yoshida M, Saikawa Y, Wada N, Ueda M, et al. Operative indications for relatively small (2-5 cm) gastrointestinal stromal tumor of the stomach based on analysis of 60 operated cases. Surgery. 2006; 139:484–492. PMID: 16627057.

36. Pister PW, Blay JY. GIST guidelines: from evidence to practice, evolving consensus in GIST management meeting monograph. 2007. In : GIST Global Opinion Leader Summit; Oct 4-8; Geneva, Switzerland.

37. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000; 231:51–58. PMID: 10636102.

38. Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol. 2006; 24:2325–2331. PMID: 16710031.

39. Sym SJ, Ryu MH, Lee JL, Chang HM, Kim TW, Kim HC, et al. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). J Surg Oncol. 2008; 98:27–33. PMID: 18452195.

40. DeMatteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009; 373:1097–1104. PMID: 19303137.

41. Kang B, Lee J, Ryu M, Im S, Park S, Kang W, et al. A phase II study of imatinib mesylate as adjuvant treatment for curatively resected high-risk localized gastrointestinal stromal tumors. J Clin Oncol. 2009; 27(S):e21515.

42. Kim TW, Ryu MH, Lee H, Sym SJ, Lee JL, Chang HM, et al. Kinase mutations and efficacy of imatinib in Korean patients with advanced gastrointestinal stromal tumors. Oncologist. 2009; 14:540–547. PMID: 19411681.

43. Joensuu H, Eriksson M, Hatrmann J, Sundby Hall K, Schutte J, Reichardt A, et al. Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: final results of a randomized trial (SSGXVIII/AIO). J Clin Oncol. 2011; 29(S):LBA1.

44. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008; 39:1411–1419. PMID: 18774375.

45. Bumming P, Andersson J, Meis-Kindblom JM, Klingenstierna H, Engström K, Stierner U, et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. Br J Cancer. 2003; 89:460–464. PMID: 12888812.

46. Loughrey MB, Mitchell C, Mann GB, Michael M, Waring PM. Gastrointestinal stromal tumour treated with neoadjuvant imatinib. J Clin Pathol. 2005; 58:779–781. PMID: 15976351.

47. Oh JS, Lee JL, Kim MJ, Ryu MH, Chang HM, Kim TW, et al. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors of stomach: report of three cases. Cancer Res Treat. 2006; 38:178–183. PMID: 19771279.

48. DeMatteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol. 2002; 33:466–477. PMID: 12094371.

49. Rankin C, von Mehren M, Blanke C, Benjamin R, Fletcher CDM, Bramwell V, et al. Dose effect of imatinib (im) in patients (pts) with metastatic GIST - Phase III Sarcoma Group Study S0033. J Clin Oncol. 2004; 22(14S):9005.

50. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004; 364:1127–1134. PMID: 15451219.

51. Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2006; 42:1093–1103. PMID: 16624552.

52. Du CY, Shi YQ, Zhou Y, Fu H, Zhao G. The analysis of status and clinical implication of KIT and PDGFRA mutations in gastrointestinal stromal tumor (GIST). J Surg Oncol. 2008; 98:175–178. PMID: 18618605.

53. Yeh CN, Chen TW, Lee HL, Liu YY, Chao TC, Hwang TL, et al. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital. Ann Surg Oncol. 2007; 14:1123–1128. PMID: 17195905.

54. Kang HJ, Ryu MH, Kim KM, Park YS, Choi J, Ryoo BY, et al. Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study. Acta Oncol. 2012; 51:528–536. PMID: 22150077.

55. Domont J, Blay J, Ray-Coquard IL, Bui Nguyen B, Adenis A, Rios M, et al. Influence of imatinib interruption and imatinib rechallenge on the residual tumor volume in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomized phase III trial. J Clin Oncol. 2011; 29(S):10054.

56. Antoch G, Kanja J, Bauer S, Kuehl H, Renzing-Koehler K, Schuette J, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med. 2004; 45:357–365. PMID: 15001674.

57. Jager PL, Gietema JA, van der Graaf WT. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nucl Med Commun. 2004; 25:433–438. PMID: 15100500.

58. Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer. 2003; 39:2012–2020. PMID: 12957455.

59. Choi H, Charnsangavej C, de Castro Faria S, Tamm EP, Benjamin RS, Johnson MM, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol. 2004; 183:1619–1628. PMID: 15547201.

60. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007; 25:1753–1759. PMID: 17470865.

61. Linton KM, Taylor MB, Radford JA. Response evaluation in gastrointestinal stromal tumours treated with imatinib: Misdiagnosis of disease progression on CT due to cystic change in liver metastases. Br J Radiol. 2006; 79:e40–e44. PMID: 16861316.

62. Desai J, Shankar S, Heinrich MC, Fletcher JA, Fletcher CDM, Tuncali K, et al. Clonal evolution of resistance to imatinib (IM) in patients (pts) with gastrointestinal stromal tumor (GIST): Molecular and radiologic evaluation of new lesions. J Clin Oncol. 2004; 22(14S):3010.

63. Bauer S, Hartmann JT, de Wit M, Lang H, Grabellus F, Antoch G, et al. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer. 2005; 117:316–325. PMID: 15900603.

64. Zalcberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer. 2005; 41:1751–1757. PMID: 16098458.

65. Park I, Ryu MH, Sym SJ, Lee SS, Jang G, Kim TW, et al. Dose escalation of imatinib after failure of standard dose in Korean patients with metastatic or unresectable gastrointestinal stromal tumor. Jpn J Clin Oncol. 2009; 39:105–110. PMID: 19052040.

66. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006; 368:1329–1338. PMID: 17046465.